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Background: Clinical significance of isolation of nontuberculous mycobacteria (NTM) from
respiratory specimens in patients with pulmonary tuberculosis is unknown. This study aimed
to investigate the prevalence and clinical impact of NTM in pulmonary tuberculosis patients.
Methods: We retrospectively reviewed data of patients with culture-confirmed pulmonary
tuberculosis from 2000 to 2006. Those in whom NTM were isolated from respiratory specimens
collected within two months before and nine months after the index culture of tuberculosis
was plated were compared with those without NTM. Patients were followed for one year after
initiation of anti-tuberculous treatment.
Results: Among 2133 patients with pulmonary tuberculosis, 48 (2.3%) with multiple and 106
(5.0%) with one isolate(s) of NTM were identified. Another 144 without NTM were selected and
compared. The one-yearmortality rateswere similar among three groups. Patientswithmultiple
NTM isolates were more likely to be symptomatic, sought medical help earlier, had smear-posi-
tive respiratory specimens, and received anti-tuberculous treatment later than those with
single/no isolate(s). Cavities were more commonly visualized radiographically in patients with
multiple/single NTM isolate(s) than thosewithout NTM isolates. Themean duration of anti-tuber-
culous treatment was 8.8 months for patients with multiple NTM isolates, significantly longer
than that in patients with single (7.6 months) and no NTM isolate(s) (7.5 months).2 23562905; fax: þ886 2 23582867.
w (J.-Y. Wang).
9 Elsevier Ltd. All rights reserved.
NTM in pulmonary TB patients 1485Conclusions: NTMwere present in the respiratory tract of 7.3% of patientswith pulmonary tuber-
culosis. Although the outcomes were similar, the presence of NTM was associated with different
clinical manifestations and had a significant impact on the treatment of tuberculosis.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Mycobacteria other than Mycobacterium tuberculosis (MTB)
complex, referred to as nontuberculous mycobacteria
(NTM), have been associated with human disease for
approximately 80 years.1 With the emergence of the Human
Immunodeficiency Virus (HIV) epidemic and the increased
use of immunosuppressants, the incidence of NTM disease
has raised evidently and NTM have accordingly been
regarded as important pathogens.2e7 The most commonly
involved site of NTM disease is the lung, accounting for 75e
94% of all NTM isolates.8,9 Over the last decade, the number
of isolates of NTM from respiratory specimens has greatly
increased and even surpassed the number of MTB isolates in
many mycobacteriology laboratories.10,11 Although pulmo-
nary tuberculosis (PTB) remains the most important myco-
bacterial disease from a public health standpoint, clinicians
are encountering more and more patients with pulmonary
disease caused by NTM.
In the official statement by the American Thoracic
Society (ATS) for managing patients with pulmonary NTM
disease, the experts conclude that other etiologies should
be appropriately excluded before the diagnosis of NTM
pulmonary disease is made.8 Because the symptoms and
radiographic findings of NTM pulmonary disease are vari-
able, nonspecific, and similar to PTB, the clinical signifi-
cance of the presence of NTM in respiratory specimens e
infection or colonization e from a patient with culture-
confirmed PTB is very difficult to determine.
In the study conductedby vanCrevel et al.,12 thepresence
ofNTM fromrespiratory specimens inpatientswithpresumed
PTB often led to diagnostic and therapeutic errors. In four of
67 patients with PTB, both NTM and MTB were cultured;
however, the authors did not describe its clinical impact. In
the present study, we aimed to evaluate the prevalence, the
various species involved, and the clinical impact of NTM in
patients with culture-confirmed PTB.
Material and methods
This retrospective study was conducted in a 2000-bed,
tertiary-care referral center in northern Taiwan. We
searched the mycobacterial laboratory registry to find all
new patients from whom MTB was isolated from respiratory
specimens from January 2000 to December 2006. Those
with NTM being isolated from respiratory specimens
collected within two months prior to and nine months after
the index culture of MTB was plated were further identi-
fied. The patients were then classified into a ‘‘multiple NTM
isolates’’ group if two or more respiratory specimens yiel-
ded the same NTM species. Others were classified as
a ‘‘single NTM isolate’’ group. The respiratory specimens
included sputum, bronchial wash, and bronchoalveolarlavage. For each patient in the multiple NTM isolates group,
we randomly selected three control subjects from the PTB
patients whose respiratory specimens were all culture-
negative for NTM (no NTM isolates group). The medical
records of each patient were reviewed and a standard case
report form was used to collect relevant clinical and labo-
ratory data, as well as the chest radiographic findings. In
this study, never-smokers were defined as patients who had
smoked <100 cigarettes in their lifetime, and current
smokers were defined as patients who smoked cigarettes
within one year of TB diagnosis. The others were defined as
ex-smokers.
Respiratory specimens were processed and pretreated as
previous described.13 Acid-fast smears (AFS) of the pro-
cessed specimens were stained with auramineerhodamine
fluorochrome and examined using standard procedures.14
Fluorochrome stain-positive smears were confirmed by the
Kinyoun method.14 Cultures were performed by inoculating
0.5 ml of the processed specimens onto Middlebrook 7H11
selective agar with antimicrobials (Remel Inc.; Lexena,
Kans.) and by fluorometric BACTEC technique (BACTEC
MGIT 960 system; BectoneDickinson Diagnostic Instrument
Systems; Sparks, MD.).13 Mycobacterial species were iden-
tified by using biochemical testing,14 and drug susceptibility
tests were performed as previously described.13 We also
retrieved the results of nucleic acid amplification test
(NAAT) for MTB in respiratory specimens if been ordered.
Throughout the study period, the NAAT for MTB was per-
formed by using the COBAS AMPLICOR MTB system (PCR;
Roche Molecular Diagnostics; Basel, Switzerland).
The diagnosis of PTB was considered early if achieved
within 14 days after the initial visit. The chest images were
independently interpreted by a radiologist and a pulmonol-
ogist. If there was disconcordance between the results, the
images were further reviewed by another pulmonologist
blinded to the results. The radiographic findings were
recorded as in our previous study.15
Standard anti-TB treatment consisted of daily isoniazid,
rifampicin, ethambutol, plus pyrazinamide (HREZ) in the
first two months (intensive phase), followed by daily HRE
for four months (continuation phase). Because resistance to
isoniazid was as high as 12% of all TB patients in this
country,16 the Centers for Disease Control, Taiwan has
recommended that ethambutol should be included in the
intensive and continuation phases if the susceptibility
testing for MTB is not available.17 Ethambutol may be dis-
continued if the results of susceptibility testing reveal an
isoniazid- and rifampicin-susceptible strain.16 The regimen
could be modified by the primary care physician according
to the presence of concomitant hepatic and/or renal
disease, adverse effects, and the results of the drug
susceptibility testing. For patients who remained smear-
positive after two-month medication, anti-TB treatment
was prolonged by extending either the intensive phase for
1486 C.-T. Huang et al.an additional month18 or the continuation phase for another
three months.19 The intensive phase and overall duration of
anti-TB treatment were thus considered prolonged if they
lasted for more than 90 days and 270 days, respectively.
The treatment outcomes were recorded according to the
definition of the World Health Organization (WHO).20 An
anti-NTM regimen was prescribed basically according to the
ATS guidelines.21 Patients were followed for at least one
year after the anti-TB treatment was started or until death.
The inter-group differences were compared by using
Student’s t-test for continuous variables, and the chi-
square test or Fisher’s exact test, as appropriate, for
categorical variables. Survival curves for each group of
patients were plotted using the KaplaneMeier method and
were compared by the log-rank test. A two-tailed p value of
less than 0.05 indicated statistical significance. Analyses
were performed using SPSS (version 10.0, Chicago, IL).Results
A total of 2133 new patients with culture-confirmed PTB
were identified. Among them, 298 patients (203 male and
95 female) were eventually included in this study; 48
(16.1%) had multiple NTM isolates from respiratory speci-
mens, 106 (35.6%) had only one NTM isolate, and 144
(48.3%) had no NTM isolates. There were two patients
whose respiratory specimens yielded different species of
NTM. One had 5 isolates of Mycobacterium avium intra-
cellular complex (MAC) and one isolate of Mycobacterium
fortuitum, and another had 11 isolates of MAC and one
isolate of Mycobacterium gordonae. Both of them were
classified into the ‘‘multiple NTM isolates’’ group. The most
common species were Mycobacterium abscessus and MAC in
the multiple NTM isolates group, and M. fortuitum and MAC
in the single NTM isolate group (Table 1). The average
number of specimens per patient was 11.7 8.2, and was
not significantly different among the three groups. In the
multiple NTM isolates group, the average number of spec-
imens culture-positive for NTM per patient was 3.6 2.3.
In the multiple NTM isolates group, M. abscessus could
be isolated throughout the whole course of anti-TBTable 1 Number of patients with different NTM species in the
Mycobacterium species Patients with multiple NTM is
M. abscessus 15 (31%)
M. avium intracellular complex 14 (29%)
M. fortuitum 5 (11%)
M. chelonae 5 (11%)
M. gordonae 4 (8%)
M. kansasii 3 (6%)
M. vaccae 1 (2%)
M. smegmatis 1 (2%)
M. scrofulaceum 0
M. xenopi 0
M. phlei 0
M. terrae 0
Unidentified 0
NTMZ nontuberculous mycobacteria.
a Data are number (%) unless otherwise mentioned.treatment and resulted in smear-positivity in 10 (67%)
patients (see Supplementary Fig. 1A). MAC was mainly iso-
lated within two months after anti-TB treatment, and
caused smear-positivity in four (29%) patients. Mycobacte-
rium chelonae was also present throughout the anti-TB
treatment. Of those with M. chelonae isolates, 80% (4 in 5)
had smear-positive respiratory specimens at initial
presentation. Overall, 52% (25 in 48) of the patients had at
least one positive culture for NTM before anti-TB
treatment.
In the single NTM isolate group, the presence of
M. fortuitum showed a bimodal distribution, peaking at
about days 0 and 120 (see Supplementary Fig. 1B). The time
course of growth of MAC was similar to that in the multiple
NTM isolates group. The majority of M. abscessus, M. gor-
donae, and M. chelonae isolates was present within one
month before or after the beginning of anti-TB treatment.
The demographic characteristics were not significantly
different among the three groups (Table 2). A significantly
higher proportion of the patients with NTM isolates, either
multiple or single, experienced weight loss and fatigue than
those without NTM isolates. The duration of symptoms was
shortest in the multiple NTM isolates group and longest in
the no NTM isolates group.
At presentation, the patients with multiple NTM isolates
were more likely to have smear-positive respiratory speci-
mens than the others, whereas the proportion of patients
whose specimens were smear-positive and culture-positive
for MTB was similar (Table 3). In patients with multiple NTM
isolates, NTM were more likely to cause smear-positivity
than MTB (27.1% vs. 20.8%). Anemia was less frequent in the
multiple NTM isolates group than the no NTM isolates group
(pZ 0.004). Patients with NTM isolates, either multiple or
single, were more than twice as likely to exhibit cavities
(33.3% and 33.0%, respectively) as those without NTM
isolates (15.3%; pZ 0.007 and 0.001, respectively).
Anti-TB treatment was started within 14 days after the
initial visit in 140 patients (47.0%). More patients in the
multiple NTM isolates group were delayed treated
compared with those in the other two groups. The most
common cause associated with delayed anti-TB treatment
was the suspicion of NTM pulmonary disease (Table 4). Of154 patients with pulmonary tuberculosis.a
olates (NZ 48) Patients with single NTM isolate (NZ 106)
15 (14%)
23 (21%)
30 (28%)
8 (8%)
12 (11%)
4 (4%)
0
1 (1%)
3 (3%)
2 (2%)
1 (1%)
1 (1%)
6 (6%)
Table 2 Characteristics of the 298 patients with pulmonary tuberculosis.a
Characteristics Patients with multiple
NTM isolates (NZ 48)
Patients with single
NTM isolate (NZ 106)
Patients with no
NTM isolates (NZ 144)
Age (year)
Mean (range) 62 (23e87) 60 (16e87) 59 (16e92)
>65 25 (52.1) 52 (49.1) 68 (47.2)
Male 32 (66.7) 76 (71.7) 95 (66.0)
Smoking
Current smoker 11 (22.9) 27 (25.5) 34 (23.6)
Ex-smoker 8 (16.7) 20 (18.9) 26 (18.1)
Underlying co-morbid condition 25 (52.1) 58 (54.7) 78 (54.2)
Diabetes mellitus 8 (16.7) 25 (23.8) 39 (27.1)
Malignancy 8 (16.7) 14 (13.3) 19 (13.2)
COPD 7 (14.6) 17 (16.0) 22 (15.3)
Use of corticosteroid 5 (10.4) 7 (6.7) 7 (4.9)
End-stage renal disease 1 (2.1) 2 (1.9) 7 (4.9)
Liver cirrhosis 1 (2.1) 1 (1.0) 5 (3.5)
AIDS 0 3 (2.9) 3 (2.1)
Presenting symptom
Cough 31 (64.4)b 54 (51.4) 63 (43.8)
Dyspnea 11 (22.9) 23 (21.9) 30 (20.8)
Hemoptysis 9 (18.8) 13 (12.4) 18 (12.5)
Chest pain 2 (4.2) 5 (4.8) 9 (6.3)
Fever 9 (18.8) 38 (36.2) 41 (28.5)
Weight loss 10 (20.8)b 24 (22.9)c 6 (4.2)
Fatigue 9 (18.8)b 19 (18.1)c 11 (7.6)
Neck mass 0 1 (1.0) 1 (0.7)
Asymptomatic 2 (4.2) 5 (4.8) 10 (6.9)
Extrapulmonary tuberculosis 4 (8.3) 8 (7.6) 7 (4.9)
Symptom duration> 3 weeks 18 (37.5)b,d 61 (57.5)c 101 (70.1)
AIDSZ acquired immunodeficiency syndrome, COPDZ chronic obstructive pulmonary disease, NTMZ nontuberculous mycobacteria.
a Data are number (%) unless otherwise mentioned.
b Significant difference (p< 0.05) between the multiple NTM isolates group and the no NTM isolates group.
c Significant difference (p< 0.05) between the single NTM isolate group and the no NTM isolates group.
d Significant difference (p< 0.05) between the multiple NTM isolates group and the single NTM isolate group.
NTM in pulmonary TB patients 1487the 48 patients in the multiple NTM isolates group, one was
initially treated as pulmonary M. chelonae disease for three
weeks before diagnosis of PTB. Another five patients
interrupted anti-TB medications in the intensive phase and
were treated for NTM pulmonary disease (M. fortuitum in
two, and one each for MAC, Mycobacterium kansasii, and
M. gordonae) for a mean of 2.8 weeks (range: 2e4 weeks).
The one-year survival and outcomes of anti-TB treatment
were similar among the three groups (Table 5; Fig. 1).
Seven patients with multiple NTM isolates and 18 patients
with single NTM isolate died at the end of study. None of
the mortalities could be attributed to NTM.
Eight (17%) patients in the multiple NTM isolates group
received anti-NTM therapy for an average of 8.9 months.
The reason for initiation of treatment was worsening cough,
dyspnea, or fever in six, and new pulmonary infiltrates with
dyspnea in the remaining two. These symptoms resolved
after NTM treatment. The species were M. abscessus in
three, two each for M. chelonae and MAC, and M. gordonae
in the remaining one. The regimens were amikacin,
cefoxitin, plus clarithromycin for M. abscessus, amikacin
plus clarithromycin for M. chelonae, ethambutol, rifam-
picin, plus clarithromycin for MAC, and ethambutol plusclarithromycin for M. gordonae. Four patients were
commenced on anti-NTM drugs during the intensive phase
of anti-TB treatment. At one-year follow-up, none of the
eight patients expired, whereas 17.5% (7 in 40) of the
patients not receiving anti-NTM therapy died. However, the
difference did not reach statistical significance.
In the single NTM isolate group, anti-NTM therapy was
prescribed for M. fortuitum in two and for M. abscessus in
one. All had persistent fever and were immunocompro-
mised; one having severe aplastic anemia, one having pure
red cell aplasia and receiving immunosuppressants, and the
remaining one having acquired immunodeficiency syndrome
with a CD4 count of 43 cells/mm3. All were alive at the end
of the study.
There were 4 smear-positive and 12 smear-negative
respiratory specimens from 16 patients were further
studied by using NAAT within 14 days after the initial visit.
All except 6 smear-negative specimens were NAAT-positive.
The 6 NAAT-negative specimens eventually yielded MTB.
However, because of culture-positivity for NTM, three (M.
fortuitum in two and MAC in one) of the 6 patients were
diagnosed as pulmonary NTM colonization or infection until
cultures finally also yielded MTB.
Table 3 Laboratory data and radiographic findings.a
Characteristics Patients with
multiple NTM isolates (NZ 48)
Patients with
single NTM isolate (NZ 106)
Patients with
no NTM isolates (NZ 144)
Sputum AFSþ, MTB and NTM 23 (47.9)b,d 28 (26.4) 25 (17.4)
AFSþ due to MTB 10 (20.8) 20 (18.9) 25 (17.4)
AFSþ due to NTM 13 (27.1)d 8 (7.5)
Drug resistant TB 13 (27.7) 29 (32.6) 43 (29.9)
Multidrug resistant TB 3 (6.4) 5 (5.6) 21 (14.6)
Leukocyte (109/l), mean SD 8172 3701 8323 3854 7935 3931
Hemoglobin (g/dl)
 12 g/dl 18 (46.2)b 47 (58.8) 85 (71.4)
> 12 g/dl 21 (53.8) 33 (41.2) 34 (28.6)
Albumin (g/l)
 3.5 g/l 12 (37.5) 34 (54.8) 63 (57.3)
> 3.5 g/l 20 (62.5) 28 (45.2) 47 (42.7)
Creatinine (mg/dl), mean SD 1.0 0.6 1.3 1.5 1.3 1.3
CXR findings
Consolidation 18 (37.5) 33 (31.1) 59 (41.0)
Fibronodular infiltrates 18 (37.5) 38 (35.8) 47 (32.6)
Fibrotic change 3 (6.3) 8 (7.5) 7 (4.9)
Miliary shadowing 1 (2.1) 8 (7.5) 5 (3.5)
Nodular lesions 3 (6.3) 8 (7.5) 23 (16.0)
Cavitation 16 (33.3)b 35 (33.0)c 22 (15.3)
Effusion 11 (22.9) 30 (28.3) 35 (24.3)
AFSZ acid-fast smear; CXRZ chest radiograph; MTBZMycobacterium tuberculosis; NTMZ nontuberculous mycobacteria;
TBZ tuberculosis.
a Data are number (%) unless otherwise mentioned.
b Significant difference (p< 0.05) between the multiple NTM isolates group and the no NTM isolates group.
c Significant difference (p< 0.05) between the single NTM isolate group and the no NTM isolates group.
d Significant difference (p< 0.05) between the multiple NTM isolates group and the single NTM isolate group.
1488 C.-T. Huang et al.Patients with multiple NTM isolates were treated for PTB
for a significantly longer duration than those with single
NTM isolate (8.8 mo vs. 7.6 mo; pZ 0.03) and those without
NTM isolates (8.8 mo vs. 7.5 mo; pZ 0.015). 58.3% of the
patients in this group received at least 9 months of anti-TB
medications with a prolonged intensive phase (Table 5).
Poor clinical response to treatment (nZ 11) was the most
important factor associated with prolonged anti-TB treat-
ment in the multiple NTM isolates group (Table 4). Of them,
eight received concomitant anti-NTM therapy. In the single
NTM isolate group, two of the four patients with poor
clinical response also underwent anti-NTM treatment
concomitantly. Interruption to treatment was the major
reason for prolonged anti-TB treatment in the single and no
NTM isolate(s) groups.
Discussion
This study demonstrates that the presence of NTM in
patients with PTB did not change the one-year survival
following anti-TB treatment, and the outcomes of patients
with multiple NTM isolates receiving and not receiving anti-
NTM therapy were similar. However, the majority of the
patients with NTM isolate(s) and poor therapeutic response
to anti-TB treatment, which was more frequently encoun-
tered in the multiple NTM isolates group, received
concomitant anti-NTM therapy. Moreover, repeatedpositive cultures with/without positive smears due to NTM
during the course of anti-TB treatment can also disturb the
judgment of the physicians and result in a longer period of
anti-TB treatment. Thus, the isolation of NTM from respi-
ratory specimens in PTB patients may not be as innocent as
we assume. Furthermore, the presence of NTM in respira-
tory specimens, especially if resulting in smear-positivity,
has a significant impact on applying infection control
strategy in the PTB patients and ultimately results in
wasting of the medical resources.
The analysis shows that a total of 2.3% of our patients
with pulmonary TB had multiple NTM isolates. Although
patients in this group were more likely to be symptomatic,
sought medical help earlier, and were more likely to have
smear-positive respiratory specimens, these did not trans-
late into early diagnosis of PTB.12,22 More than half (26 in
48) of the NTM isolates in this group were rapidly growing
mycobacteria. Before anti-TB treatment, approximately
half of the patients in the multiple NTM isolates group had
at least one positive culture for NTM, and about two-thirds
of them were initially suspected to have NTM pulmonary
disease. This situation certainly complicated the decision-
making of the physicians and caused the diagnosis of PTB to
be deferred in approximately one-third of the patients with
multiple NTM isolates.
Therefore, understanding the clues for the presence of
NTM in PTB patients is practically important. Although our
Table 4 Factors associated with delayed and prolonged anti-TB treatment.a
Characteristics Patients with multiple
NTM isolates
Patients with single
NTM isolate
Patients with no
NTM isolates
Delayed anti-TB treatment> 14 days
Total patient No. 35 51 72
Suspected NTM pulmonary
disease
15 (42.9) 5 (9.8) 0
Atypical CXR finding for TB 11 (31.4) 19 (37.3) 37 (51.4)
Negative acid-fast smear 5 (14.3) 20 (39.2) 26 (36.1)
Others 4 (11.4) 7 (13.7) 9 (12.5)
Prolonged anti-TB treatment> 270 days
Total patient No. 28 40 41
Poor clinical response to
treatment
11 (39.3) 4 (10.0) 2 (4.9)
Treatment interruption 7 (24.9) 15 (37.5) 16 (39.0)
Drug resistance 4 (14.2) 11 (27.5) 14 (34.2)
Repeated positive NTM
cultures
2 (7.1) 0 0
Treatment failure 1 (3.6) 5 (12.5) 7 (17.1)
Coexistent
extrapulmonary TB
1 (3.6) 2 (5.0) 1 (2.4)
Unrecognized reason 2 (7.1) 3 (7.5) 1 (2.4)
CXRZ chest radiograph, NTMZ nontuberculous mycobacteria, TBZ tuberculosis.
a Data are number (%) unless otherwise mentioned.
NTM in pulmonary TB patients 1489study reveals some differences in the symptoms and
radiographic findings between three groups, none of them
are pathognomonic.23 In addition, applying an NAAT that
detects MTB DNA may not be very helpful, or even be
misleading, for the diagnosis of PTB in this situation. ToTable 5 Diagnosis, management, and outcome.a
Characteristics Patients with
multiple NTM isolates (NZ 48)
Initial visit to anti-TB treatment
Mean SD (days) 38.6 36.1b,c
>14 days 35 (72.9)b,c
Duration of intensive phase
Mean SD (days) 106.1 53.2b,c
>90 days 25 (52.1)b,c
Duration of continuation phase
Mean SD (days) 165.7 98.3
Overall duration of treatment
Mean SD (days) 263.0 97.3b,c
>270 days 28 (58.3)b,c
Outcome of anti-TB treatment at one-year follow-up
Treatment completed 32 (66.6)
Treatment failure 1 (2.1)
Default 2 (4.2)
Died 7 (14.6)
Ongoing treatment 6 (12.5)
NTMZ nontuberculous mycobacteria; TBZ tuberculosis.
a Data are number (%) unless otherwise mentioned.
b Significant difference (p< 0.05) between the multiple NTM isolate
c Significant difference (p< 0.05) between the multiple NTM isolateavoid these errors, a meticulous clinical evaluation is
important, and probably an NAAT detecting the gene
expression (RNA) of MTB will help resolve the uncertainty
and prevent unnecessary change in the treatment plan.
However, further studies are necessary.Patients with
single NTM isolate (NZ 106)
Patients with
no NTM isolates (NZ 144)
24.3 26.7 23.9 22.3
51 (48.1) 72 (50.0)
83.8 41.5 74.6 41.8
22 (20.8) 34 (23.6)
154.3 100.4 151.4 80.3
227.8 107.1 226.0 76.1
40 (37.7) 41 (28.5)
75 (70.7) 102 (70.8)
5 (4.7) 7 (4.9)
1 (1.0) 1 (0.7)
18 (17.0) 23 (16.0)
7 (6.6) 11 (7.6)
s group and the no NTM isolates group.
s group and the single NTM isolate group.
Figure 1 Survival curves for pulmonary tuberculosis patients
with multiple, single, or no isolate(s) of NTM were plotted
using the KaplaneMeier method. NTMZ nontuberculous
mycobacteria.
1490 C.-T. Huang et al.AlthoughMAC is reportedmost commonlyworldwide,24 its
prevalence (24%) in our study was obviously lower than that
in Australia (91%),25 Japan (71%),26 and even our neighboring
country, Hong Kong (54%).27 Rapidly growing mycobacteria,
particularly M. abscessus and M. fortuitum, are well-known
but uncommon causes of pulmonary disease.10,28,29
However, M. abscessus, M. chelonae, and M. fortuitum
together accounts for more than half of the NTM isolates in
our study. Although the increase in the proportion of rapidly
growing mycobacteria among all NTM isolates had been
observed from 1992 to 2001 in Taiwan,30 the reported rate
(34.5%) remained evidently lower than that from this study
(78 in 154, 50.6%). The differences in methodology
(prospective vs. retrospective), patient selection (PTB
patients vs. general population), and geographical variation
are probably responsible for the discrepancy. This highlights
the importance of understanding the local epidemiology in
the management of various patient populations with NTM
isolated from their respiratory specimens.
There were some limitations in this study. First, in this
retrospective study, the results were incomplete and
biased because mycobacteriologic evaluation of the respi-
ratory specimens was not standardized. Second, because
NTM pulmonary infection is usually a chronic indolent
disease,8 the follow-up duration was not sufficient to
thoroughly evaluate the clinical consequences of our
patients with NTM isolates. Third, given the small number
of cases, the significance of some NTM species might be
overlooked and the power of the statistical analysis was
limited. Finally, in the absence of histologic examination of
the lung, we were unable to accurately define the role of
different NTM species in PTB patients. Large-scale,
prospective, long-term follow-up studies accompanied by
sampling of lung tissue are needed to clarify these issues.
In conclusion, about 7.3% of the patients with PTB have
NTM isolates in their respiratory specimens. The presence
of NTM in these patients has a significant impact on clinical
judgment and patient management, although the patients
seem not to have a worse prognosis. A thorough under-
standing of the epidemiology, clinical manifestations, and
prognostic impact of NTM under the special situation is
mandatory for physicians to make a prompt diagnosis and
choose an appropriate treatment plan.Conflict of interest statement
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